Effect of omega-3 acid ethyl esters on left ventricular remodeling after acute myocardial infarction

Circulation

Volumn 134, Issue 5, 2016, Pages 378-391

  Heydari, Bobak ^a   Abdullah, Shuaib ^a   Pottala, James V ^b   Shah, Ravi ^a,c   Abbasi, Siddique ^a   Mandry, Damien ^a   Francis, Sanjeev A ^c   Lumish, Heidi ^c   Ghoshhajra, Brian B ^c   Hoffmann, Udo ^c   Appelbaum, Evan ^d   Feng, Jiazhuo H ^a   Blankstein, Ron ^a   Steigner, Michael ^a   McConnell, Joseph P ^e   Harris, William ^b,f   Antman, Elliott M ^a   Jerosch Herold, Michael ^a   Kwong, Raymond Y ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF SOUTH DAKOTA   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e Health Diagnostic Laboratory Inc   (United States)

^f OmegaQuant Analytics   (United States)

Author keywords

endomyocardial fibrosis; fatty acids, omega 3; infarction; magnetic resonance imaging; ventricular remodeling

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; CORN OIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOCOSAHEXAENOIC ACID; DOCOSAPENTAENOIC ACID; FATTY ACID; GADOLINIUM; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; INSULIN; LINOLEIC ACID; LINOLENIC ACID; OMEGA 3 ACID ETHYL ESTER; PLACEBO; PRASUGREL; OMEGA 3 FATTY ACID; TROPONIN T;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLEEDING; CARDIOVASCULAR MAGNETIC RESONANCE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE; EVIDENCE BASED MEDICINE; FATTY ACID BLOOD LEVEL; FEMALE; HEART; HEART FAILURE; HEART INDEX; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART MUSCLE FIBROSIS; HEART SCINTISCANNING; HEART VENTRICLE REMODELING; HEMATOCRIT; HUMAN; HYPERTENSION; INTENTION TO TREAT ANALYSIS; LEFT VENTRICULAR REMODELING; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SERUM; SIDE EFFECT; TONGUE SWELLING; TREATMENT DURATION; VASCULITIS; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; DRUG EFFECTS; FIBROSIS; HEART INFARCTION; HEART VENTRICLE; INFLAMMATION; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGAN SIZE; SYSTOLE; TREATMENT OUTCOME; VIROLOGY;

AGED; BIOMARKERS; DOUBLE-BLIND METHOD; FATTY ACIDS, OMEGA-3; FEMALE; FIBROSIS; HEART VENTRICLES; HUMANS; INFLAMMATION; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NAUSEA; ORGAN SIZE; PROSPECTIVE STUDIES; SYSTOLE; TREATMENT OUTCOME; TROPONIN T; VENTRICULAR REMODELING;

EID: 84982806121     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.115.019949     Document Type: Article

References (37)

1. Mozaffarian D, Rimm EB. Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA. 2006; 296: 1885-1899. doi: 10.1001/jama.296.15.1885
2. De Caterina R. n-3 fatty acids in cardiovascular disease. N Engl J Med. 2011; 364: 2439-2450. doi: 10.1056/NEJMra1008153
3. Marchioli R, Barzi F, Bomba E, Chieffo C, Di Gregorio D, Di Mascio R, Franzosi MG, Geraci E, Levantesi G, Maggioni AP, Mantini L, Marfisi RM, Mastrogiuseppe G, Mininni N, Nicolosi GL, Santini M, Schweiger C, Tavazzi L, Tognoni G, Tucci C, Valagussa F. GISSIPrevenzione Investigators. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell?Infarto Miocardico (GISSI)-Prevenzione. Circulation. 2002; 105: 1897-1903
4. Rauch B, Schiele R, Schneider S, Diller F, Victor N, Gohlke H, Gottwik M, Steinbeck G, Del Castillo U, Sack R, Worth H, Katus H, Spitzer W, Sabin G, Senges J. OMEGA Study Group. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-Adjusted therapy after myocardial infarction. Circulation. 2010; 122: 2152-2159. doi: 10.1161/CIRCULATIONAHA.110.948562
5. Chan W, Duffy SJ, White DA, Gao XM, Du XJ, Ellims AH, Dart AM, Taylor AJ. Acute left ventricular remodeling following myocardial infarction: coupling of regional healing with remote extracellular matrix expansion. JACC Cardiovasc Imaging. 2012; 5: 884-893. doi: 10.1016/j.jcmg.2012.03.015
6. Krauss RM, Eckel RH, Howard B, Appel LJ, Daniels SR, Deckelbaum RJ, Erdman JW Jr, Kris-Etherton P, Goldberg IJ, Kotchen TA, Lichtenstein AH, Mitch WE, Mullis R, Robinson K, Wylie-Rosett J, St Jeor S, Suttie J, Tribble DL, Bazzarre TL. Revision 2000: a statement for healthcare professionals from the Nutrition Committee of the American Heart Association. J Nutr. 2001; 131: 132-146
7. Hsu LY, Natanzon A, Kellman P, Hirsch GA, Aletras AH, Arai AE. Quantitative myocardial infarction on delayed enhancement MRI. Part I: Animal validation of an automated feature analysis and combined thresholding infarct sizing algorithm. J Magn Reson Imaging. 2006; 23: 298-308. doi: 10.1002/jmri.20496
8. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, Pennell DJ, Rumberger JA, Ryan T, Verani MS. American Heart Association Writing Group on Myocardial Segmentation and Registration for Cardiac Imaging. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation. 2002; 105: 539-542
9. Deichmann R, Haase A. Quantification of T1 values by SNAPSHOTFLASH NMR imaging. J Magn Reson. 1992; 96: 608-612
10. Coelho-Filho OR, Mongeon FP, Mitchell R, Moreno H Jr, Nadruz W Jr, Kwong R, Jerosch-Herold M. Role of transcytolemmal water-exchange in magnetic resonance measurements of diffuse myocardial fibrosis in hypertensive heart disease. Circ Cardiovasc Imaging. 2013; 6: 134-141. doi: 10.1161/CIRCIMAGING.112.979815
11. Jerosch-Herold M, Sheridan DC, Kushner JD, Nauman D, Burgess D, Dutton D, Alharethi R, Li D, Hershberger RE. Cardiac magnetic resonance imaging of myocardial contrast uptake and blood flow in patients affected with idiopathic or familial dilated cardiomyopathy. Am J Physiol Heart Circ Physiol. 2008; 295: H1234-H1242. doi: 10.1152/ajpheart.00429.2008
12. Harris WS, Sands SA, Windsor SL, Ali HA, Stevens TL, Magalski A, Porter CB, Borkon AM. Omega-3 fatty acids in cardiac biopsies from heart transplantation patients: correlation with erythrocytes and response to supplementation. Circulation. 2004; 110: 1645-1649. doi: 10.1161/01.CIR.0000142292.10048.B2
13. Harris WS, Von Schacky C. The Omega-3 Index: a new risk factor for death from coronary heart disease? Prev Med. 2004; 39: 212-220. doi: 10.1016/j.ypmed.2004.02.030
14. Fitzmaurice GM, Laird NM, Ware JH. Applied Longitudinal Analysis. 2nd ed. Hoboken, NJ: Wiley; 2011
15. Greenberg B, Quinones MA, Koilpillai C, Limacher M, Shindler D, Benedict C, Shelton B. Effects of long-Term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation. 1995; 91: 2573-2581
16. Wong M, Staszewsky L, Latini R, Barlera S, Volpi A, Chiang YT, Benza RL, Gottlieb SO, Kleemann TD, Rosconi F, Vandervoort PM, Cohn JN. Val-HeFT Heart Failure Trial Investigators. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J Am Coll Cardiol. 2002; 40: 970-975
17. Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med. 1988; 319: 80-86. doi: 10.1056/NEJM198807143190204
18. O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX, Anderson JL, Jacobs AK, Halperin JL, Albert NM, Brindis RG, Creager MA, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Kushner FG, Ohman EM, Stevenson WG, Yancy CW. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013; 127: e362-e425. doi: 10.1161/CIR.0b013e3182742cf6
19. Mongeon FP, Jerosch-Herold M, Coelho-Filho OR, Blankstein R, Falk RH, Kwong RY. Quantification of extracellular matrix expansion by CMR in infiltrative heart disease. JACC Cardiovasc Imaging. 2012; 5: 897-907. doi: 10.1016/j.jcmg.2012.04.006
20. Broberg CS, Chugh SS, Conklin C, Sahn DJ, Jerosch-Herold M. Quantification of diffuse myocardial fibrosis and its association with myocardial dysfunction in congenital heart disease. Circ Cardiovasc Imaging. 2010; 3: 727-734. doi: 10.1161/CIRCIMAGING. 108.842096
21. Harris WS, Pottala JV, Lacey SM, Vasan RS, Larson MG, Robins SJ. Clinical correlates and heritability of erythrocyte eicosapentaenoic and docosahexaenoic acid content in the Framingham Heart Study. Atherosclerosis. 2012; 225: 425-431. doi: 10.1016/j.atherosclerosis. 2012.05.030
22. Neilan TG, Coelho-Filho OR, Shah RV, Abbasi SA, Heydari B, Watanabe E, Chen Y, Mandry D, Pierre-Mongeon F, Blankstein R, Kwong RY, Jerosch-Herold M. Myocardial extracellular volume fraction from T1 measurements in healthy volunteers and mice: relationship to aging and cardiac dimensions. JACC Cardiovasc Imaging. 2013; 6: 672-683. doi: 10.1016/j.jcmg.2012.09.020
23. Billman GE, Hallaq H, Leaf A. Prevention of ischemia-induced ventricular fibrillation by omega 3 fatty acids. Proc Natl Acad Sci U S A. 1994; 91: 4427-4430
24. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992; 327: 669-677. doi: 10.1056/NEJM199209033271001
25. Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. J Am Coll Cardiol. 1997; 29: 1060-1066
26. White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation. 1987; 76: 44-51
27. St John Sutton M, Pfeffer MA, Plappert T, Rouleau JL, Moyé LA, Dagenais GR, Lamas GA, Klein M, Sussex B, Goldman S. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation. 1994; 89: 68-75
28. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001; 357: 1385-1390
29. Doughty RN, Whalley GA, Walsh HA, Gamble GD, López-Sendón J, Sharpe N. CAPRICORN Echo Substudy Investigators. Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy. Circulation. 2004; 109: 201-206. doi: 10.1161/01. CIR.0000108928.25690.94
30. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 1990; 81: 1161-1172
31. Neschen S, Morino K, Rossbacher JC, Pongratz RL, Cline GW, Sono S, Gillum M, Shulman GI. Fish oil regulates adiponectin secretion by a peroxisome proliferator-Activated receptor-gamma-dependent mechanism in mice. Diabetes. 2006; 55: 924-928
32. Itoh M, Suganami T, Satoh N, Tanimoto-Koyama K, Yuan X, Tanaka M, Kawano H, Yano T, Aoe S, Takeya M, Shimatsu A, Kuzuya H, Kamei Y, Ogawa Y. Increased adiponectin secretion by highly purified eicosapentaenoic acid in rodent models of obesity and human obese subjects. Arterioscler Thromb Vasc Biol. 2007; 27: 1918-1925. doi: 10.1161/ATVBAHA.106.136853
33. Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan W, Li P, Lu WJ, Watkins SM, Olefsky JM. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulinsensitizing effects. Cell. 2010; 142: 687-698. doi: 10.1016/j. cell.2010.07.041
34. Weinberg EO, Shimpo M, De Keulenaer GW, MacGillivray C, Tominaga S, Solomon SD, Rouleau JL, Lee RT. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation. 2002; 106: 2961-2966
35. Sabatine MS, Morrow DA, Higgins LJ, MacGillivray C, Guo W, Bode C, Rifai N, Cannon CP, Gerszten RE, Lee RT. Complementary roles for biomarkers of biomechanical strain ST2 and N-Terminal prohormone B-Type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation. 2008; 117: 1936-1944. doi: 10.1161/CIRCULATIONAHA.107.728022
36. Eggers KM, Armstrong PW, Califf RM, Simoons ML, Venge P, Wallentin L, James SK. ST2 and mortality in non-ST-segment elevation acute coronary syndrome. Am Heart J. 2010; 159: 788-794. doi: 10.1016/j.ahj.2010.02.022
37. Chen J, Shearer GC, Chen Q, Healy CL, Beyer AJ, Nareddy VB, Gerdes AM, Harris WS, O'Connell TD, Wang D. Omega-3 fatty acids prevent pressure overload-induced cardiac fibrosis through activation of cyclic GMP/protein kinase G signaling in cardiac fibroblasts. Circulation. 2011; 123: 584-593. doi: 10.1161/CIRCULATIONAHA.110.971853